Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up

Àttux, Cecília; Quintana, Maria Inês; Chaves, Ana Cristina

doi:10.1590/s1516-44462006005000061

Cited by 27 publications

(22 citation statements)

References 24 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data on metabolic changes were in alignment with recent prospective studies in first-episode patents (Attux et al, 2007;Perez-Iglesias et al, 2008;Saddichha et al, 2007;Srisurapanont et al, 2007) and confirmed the differences between SGA in their liability to induce metabolic changes (Cohn and Sernyak, 2006;L'Italien et al, 2007;Newcomer, 2005;van Winkel et al, 2008).…”

Section: Discussionsupporting

confidence: 90%

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review

Hert

Schreurs

Sweers

et al. 2008

Schizophrenia Research

220

118

View full text Add to dashboard Cite

The presence of the metabolic syndrome (MetS) is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of MetS in patients with schizophrenia at the onset of the disorder and specifically no data on patients treated in the era when only first-generation antipsychotics were available.Methods: Data from a historic cohort of consecutively admitted first-episode patients with schizophrenia treated with first-generation antipsychotics (FGAs) were compared with an age and sex matched series of consecutive first-episode patients treated only with second-generation antipsychotics (SGAs). Rates of MetS were compared at baseline and after on average 3 years of treatment exposure.Results: At first episode there was no difference in the prevalence of MetS between the historic and the current cohort. Rates of MetS increased over time in both groups, but patients started on SGAs had a three times higher incidence rate of MetS (Odds Ratio 3.6, CI 1.7-7.5). The average increase in weight and body mass index was twice as high in patients started on SGA. The difference between the FGA and SGA group was no longer significant when patients started on clozapine and olanzapine were excluded. Conclusion:Rates of MetS at the first episode of schizophrenia today are not different from those of patients 15 to 20 years ago. This finding counters the notion that the high rates of metabolic abnormalities in patients with schizophrenia currently reported are mainly due to lifestyle changes over time in the general population. Some SGAs have a significantly more negative impact on the incidence of MetS compared to FGAs in first-episode patients.

show abstract

Section: Discussionsupporting

confidence: 90%

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review

Hert

Schreurs

Sweers

et al. 2008

Schizophrenia Research

220

118

View full text Add to dashboard Cite

show abstract

“…Hypotheses on the association between schizophrenia and diabetes (adapted from Leucht et al [2007aLeucht et al [ , 2007b of the study group varied, however male patients appeared to be over represented. In most studies the mean age of participants in the study group was over 40 years of age, and only a few studies referred to patients with first episode schizophrenia [Attux et al 2007;Saddichha et al 2007;De Hert et al 2008b;Saddichha et al 2008;Curtis et al 2011]. The predominant diagnosis of patients studied was schizophrenia, however a great number of studies also included patients with schizoaffective disorder and other psychotic disorders.…”

Section: Study Selectionmentioning

confidence: 99%

“…Incidence of metabolic syndrome A minority of studies calculated incidence rates of MetS [Attux et al 2007;L'Italien et al 2007;Saddichha et al 2007;Srisurapanont et al 2007;De Hert et al 2008b;Meyer et al 2008;Kim et al 2010;Kraemer et al 2010]. The results were hardly comparable in this field as incidence rates were calculated for various time periods, from 6 weeks up to 1 year.…”

Section: Metabolic Syndrome and Lifestyle Habitsmentioning

confidence: 99%

The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review

Papanastasiou¹

2012

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Metabolic syndrome: introduction The metabolic syndrome (MetS, also known as syndrome X, syndrome of chronic cardiovascular disease and Reaven's syndrome) is a constellation of different conditions, including abdominal obesity, insulin resistance, dyslipidaemia and elevated blood pressure. All components of the MetS (with obesity holding a central role in its development) have been recognized as independent risk factors for cardiovascular disease and so the presence of MetS is associated with other comorbidities such as the prothrombotic state, proinflammatory state, nonalcoholic fatty liver disease and reproductive disorders [Cornier et al. 2008]. Owing to its multiple components, many definitions have

show abstract

“…Some recent studies have also emphasized the relevance of the problem in Brazil, particularly in psychotic disorders 33,34 . Teixeira and Rocha 12 , applying NCEP-ATP III criteria, found elevated rates of MS in psychiatric inpatients with schizophrenia (40%) BD (42.9%) and major depressive disorder (52.9%).…”

Section: Discussionmentioning

confidence: 99%

Resistência à insulina e síndrome metabólica em pacientes ambulatoriais com transtorno do humor bipolar

Gomes¹,

Magalhães²,

Kunz³

et al. 2010

Rev. psiquiatr. clín.

View full text Add to dashboard Cite

Background: Bipolar disorder (BD) is associated with significant morbidity and mortality from metabolic diseases. There is a paucity of data regarding insulin resistance (IR) and its relationship with the metabolic syndrome (MS) in bipolar patients. Objective: To evaluate the prevalence of both IR and MS in BD outpatients and to assess clinical criteria associated with IR. Method: Cross-sectional study in 65 DSM-IV-TR BD patients consecutively assessed at the Bipolar Disorder Program at Hospital de Clínicas de Porto Alegre, Brazil. IR was diagnosed by the homeostatic model assessment -insulin resistance (HOMA-IR) and MS was diagnosed using three different definitions: National Cholesterol Educational Program -Adult Treatment Panel III (NCEP-ATP III); NCEP-ATP III modified criteria and International Diabetes Federation. Results: IR was present in 43.1% of the sample (women 40%, men 44.4%). The prevalence of MS defined by the NCEP-ATP III criteria was 32.3%, NCEP-ATP III modified was 40% and IDF was 41.5%. NCEP-ATP III modified criteria showed the best tradeoff between sensitivity (78.6%) and specificity (89.2%) to detect insulin resistance. Waist circumference was the clinical parameter most associated with IR. Discussion: Current MS criteria may provide reasonable sensitivity and specificity for the detection of IR in BD patients. Abdominal obesity is closely related to IR in this patient population.

show abstract

Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up

Abstract: Clinicians should be aware of these risks, choose an antipsychotic that causes less weight gain and should monitor these patients carefully, and recommend prophylactic measures as diet restriction and physical activities.

Cited by 27 publications

References 24 publications

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review

The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review

Resistência à insulina e síndrome metabólica em pacientes ambulatoriais com transtorno do humor bipolar

Contact Info

Product

Resources

About